2-chloro-5-[5-[(Z)-[3-[(4-fluorophenyl)methyl]-2,4-dioxo-thiazolidin-5-ylidene]methyl]-2-furyl]benzoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-5-[5-[(Z)-[3-[(4-fluorophenyl)methyl]-2,4-dioxo-thiazolidin-5-ylidene]methyl]-2-furyl]benzoic acid
• 英文别名: 2-chloro-5-[5-[(Z)-[3-[(4-fluorophenyl)methyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl]benzoic acid
• 化学式: C₂₂H₁₃ClFNO₅S
• 分子量: 457.9
• InChiKey: LRYWBXWQVDGJMW-GRSHGNNSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18
  申请人：Adhaere Pharamaceuticals, Inc.

  公开号：EP3243821A1

  公开（公告）日：2017-11-15

  A pharmaceutical formulation of a β2 integrin agonist including an effective amount of a β2 integrin agonist and a pharmaceutically acceptable carrier. A method of activating β2 integrins by interacting the β2 integrins with a β2 integrin agonist. A method of treating a patient by administering an effective amount of a β2integrin agonist, and activating β2 integrins. A method of treating inflammation by administering a β2 integrin agonist to a patient with inflammation, activating β2 integrins, and reducing inflammation. Methods of treating and/or preventing renal ischemia-reperfusion (I/R) injury, reducing injury in a patient due to insertion of a stent, performing an assay for the identification of small molecule modulators of β2 integrins, detecting a disease in a patient, and improving the general wellness of a patient.

  β2 整合素激动剂的药物制剂，包括有效量的β2 整合素激动剂和药学上可接受的载体。一种通过β2整合素与β2整合素激动剂相互作用来激活β2整合素的方法。一种通过施用有效量的β2整合素激动剂并激活β2整合素来治疗患者的方法。一种治疗炎症的方法，给炎症患者施用β2整合素激动剂，激活β2整合素，减轻炎症。治疗和/或预防肾缺血再灌注（I/R）损伤的方法，减少患者因插入支架而造成的损伤，进行β2整合素小分子调节剂的鉴定试验，检测患者的疾病，改善患者的总体健康状况。
• Compounds and methods for regulating integrins
  申请人：ADHAERE PHARMACEUTICALS, INC.

  公开号：US10239871B2

  公开（公告）日：2019-03-26

  A method of treating inflammation, by administering an effective amount of a β2 integrin agonist to a patient, and reducing inflammation. A method of treating cancer, by administering an effective amount of a β2 integrin agonist to a patient, and reducing tumor growth. A method of treating a patient exposed to radiation, by administering an effective amount of a β2 integrin agonist to the patient after radiation exposure, and mitigating the effects of radiation exposure in the patient. A method of preventing effects of radiation, by administering an effective amount of a β2 integrin agonist to the patient prior to radiation exposure, and preventing the effects of radiation exposure on the patient. A method of treating acquired bone marrow failure (BMF), by administering an effective amount of a β2 integrin agonist to a patient. Methods of improving the health of damaged vasculature in a patient and activating β2 integrins.

  一种治疗炎症的方法，通过向患者施用有效量的β2整合素激动剂来减轻炎症。一种治疗癌症的方法，向患者施用有效量的β2整合素激动剂，减少肿瘤生长。一种治疗暴露于辐射的患者的方法，方法是在患者暴露于辐射后向其施用有效量的β2整合素激动剂，并减轻辐射对患者的影响。一种预防辐射影响的方法，通过在辐照前向患者施用有效量的β2整合素激动剂，预防辐照对患者的影响。一种治疗获得性骨髓衰竭（BMF）的方法，向患者施用有效量的β2整合素激动剂。改善患者受损血管健康状况并激活β2整合素的方法。
• Compositions and methods to treat solid tumors
  申请人：Wayne State University

  公开号：US10336827B2

  公开（公告）日：2019-07-02

  Compositions and methods that utilize anti-CD11b antibodies, anti-CD18 antibodies, anti-myeloperoxidase (MPO) antibodies, anti-integrin αV antibodies, anti-integrin β1 antibodies, Abciximab, neutrophil inhibitory factor (NIF) protein, and/or combinations thereof to treat solid tumors are described.

  本文描述了利用抗 CD11b 抗体、抗 CD18 抗体、抗骨髓过氧化物酶 (MPO) 抗体、抗整合素 αV 抗体、抗整合素 β1 抗体、阿昔单抗、中性粒细胞抑制因子 (NIF) 蛋白和/或其组合治疗实体瘤的组合物和方法。
• COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18
  申请人：Adhaere Pharamaceuticals, Inc.

  公开号：EP2591092B1

  公开（公告）日：2017-06-21
• COMPOSITIONS FOR REGULATING INTEGRINS
  申请人：GB006, Inc.

  公开号：EP2838614B1

  公开（公告）日：2019-09-11